A citation-based method for searching scientific literature

Orville G Kolterman, John B Buse, Mark S Fineman, Eling Gaines, Sonja Heintz, Thomas A Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang, Alain D Baron. J Clin Endocrinol Metab 2003
Times Cited: 421







List of co-cited articles
1156 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
Daniel J Drucker, John B Buse, Kristin Taylor, David M Kendall, Michael Trautmann, Dongliang Zhuang, Lisa Porter. Lancet 2008
720
28

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
25


Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Ralph A DeFronzo, Robert E Ratner, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
21

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Thomas Blevins, John Pullman, Jaret Malloy, Ping Yan, Kristin Taylor, Christine Schulteis, Michael Trautmann, Lisa Porter. J Clin Endocrinol Metab 2011
300
19

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
900
18

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
John B Buse, Robert R Henry, Jenny Han, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2004
942
18

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.
Orville G Kolterman, Dennis D Kim, Larry Shen, James A Ruggles, Loretta L Nielsen, Mark S Fineman, Alain D Baron. Am J Health Syst Pharm 2005
299
18


Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Ralph A DeFronzo, Ted Okerson, Prabhakar Viswanathan, Xuesong Guan, John H Holcombe, Leigh MacConell. Curr Med Res Opin 2008
288
16

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
16

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Michaela Diamant, Luc Van Gaal, Stephen Stranks, Justin Northrup, Dachuang Cao, Kristin Taylor, Michael Trautmann. Lancet 2010
324
16

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao, Marilyn K Boardman, Mark Fineman,[...]. Lancet 2013
338
16

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers.
C M Edwards, S A Stanley, R Davis, A E Brynes, G S Frost, L J Seal, M A Ghatei, S R Bloom. Am J Physiol Endocrinol Metab 2001
352
15

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
M A Nauck, U Niedereichholz, R Ettler, J J Holst, C Orskov, R Ritzel, W H Schmiegel. Am J Physiol 1997
514
15

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
David Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, Ajay Kumar, Jose G González, Melanie Chan, Anne M Wolka, Marilyn K Boardman. Diabetes Care 2012
244
15

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Richard M Bergenstal, Carol Wysham, Leigh Macconell, Jaret Malloy, Brandon Walsh, Ping Yan, Ken Wilhelm, Jim Malone, Lisa E Porter. Lancet 2010
439
15

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A Kothare, Michael Trautmann, Mark Fineman, Kristin Taylor. Diabetes Care 2007
336
15


Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
Helle Linnebjerg, Soomin Park, Prajakti A Kothare, Michael E Trautmann, Kenneth Mace, Mark Fineman, Ian Wilding, Michael Nauck, Michael Horowitz. Regul Pept 2008
170
14

Glucagon-like peptide-1 7-36: a physiological incretin in man.
B Kreymann, G Williams, M A Ghatei, S R Bloom. Lancet 1987
14



Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Ulrich Werner, Guido Haschke, Andreas W Herling, Werner Kramer. Regul Pept 2010
115
14

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Jesper Lau, Paw Bloch, Lauge Schäffer, Ingrid Pettersson, Jane Spetzler, Jacob Kofoed, Kjeld Madsen, Lotte Bjerre Knudsen, James McGuire, Dorte Bjerre Steensgaard,[...]. J Med Chem 2015
304
14

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
14


PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
667
13

Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
Antonio Cervera, Estela Wajcberg, Apiradee Sriwijitkamol, Marianella Fernandez, Pengou Zuo, Curtis Triplitt, Nicolas Musi, Ralph A DeFronzo, Eugenio Cersosimo. Am J Physiol Endocrinol Metab 2008
118
12

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia.
Kristine B Degn, Birgitte Brock, Claus B Juhl, Christian B Djurhuus, Jaime Grubert, Dennis Kim, Jenny Han, Kristin Taylor, Mark Fineman, Ole Schmitz. Diabetes 2004
198
12


Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.
Frauke Fehse, Michael Trautmann, Jens J Holst, Amy E Halseth, Nuwan Nanayakkara, Loretta L Nielsen, Mark S Fineman, Dennis D Kim, Michael A Nauck. J Clin Endocrinol Metab 2005
228
11

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
389
11

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Mark S Fineman, K F Mace, M Diamant, T Darsow, B B Cirincione, T K Booker Porter, L A Kinninger, M E Trautmann. Diabetes Obes Metab 2012
103
11

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
211
11




Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
Mary Beth DeYoung, Leigh MacConell, Viren Sarin, Michael Trautmann, Paul Herbert. Diabetes Technol Ther 2011
157
11

Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
Wolfgang Glaesner, Andrew Mark Vick, Rohn Millican, Bernice Ellis, Sheng-Hung Tschang, Yu Tian, Krister Bokvist, Martin Brenner, Anja Koester, Niels Porksen,[...]. Diabetes Metab Res Rev 2010
159
11

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Kristine B Degn, Claus B Juhl, Jeppe Sturis, Grethe Jakobsen, Birgitte Brock, Visvanathan Chandramouli, Joergen Rungby, Bernard R Landau, Ole Schmitz. Diabetes 2004
331
11

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
11

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
10



Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Robert J Heine, Luc F Van Gaal, Don Johns, Michael J Mihm, Mario H Widel, Robert G Brodows. Ann Intern Med 2005
600
10


Mechanisms of action of glucagon-like peptide 1 in the pancreas.
Máire E Doyle, Josephine M Egan. Pharmacol Ther 2007
398
10



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.